Chronic Kidney Disease And Complications - USMLE Step 2

SECTION 1

Historical Context & Motivation

The recognition of chronic kidney disease (CKD) as a distinct clinical entity evolved over centuries, beginning with early anatomical observations of shrunken, fibrotic kidneys at autopsy. Before the advent of modern serology, clinicians relied on gross pathological findings and the clinical syndrome of uremia—nausea, confusion, pericarditis, and eventual death—to diagnose end-stage renal failure. The progressive understanding of renal physiology, glomerular filtration, and tubular function throughout the nineteenth and twentieth centuries laid the groundwork for the contemporary classification and management of CKD. Today, CKD affects approximately 15% of the U.S. adult population and stands as one of the most significant contributors to cardiovascular morbidity and mortality worldwide, making it a critical topic for clinical examinations and patient care alike.

1827 • Richard Bright's Observations

Richard Bright published correlations between edema, proteinuria, and shrunken kidneys at autopsy, establishing Bright's disease as the first recognized form of chronic nephropathy.

1960s • Advent of Chronic Dialysis

Belding Scribner developed the arteriovenous shunt, enabling long-term hemodialysis and transforming end-stage renal disease from a universally fatal condition into a manageable chronic illness.

1976 • Cockcroft-Gault Equation

Cockcroft and Gault introduced a formula to estimate creatinine clearance from serum creatinine, age, weight, and sex, providing a practical bedside tool for assessing renal function.

2002 • NKF-KDOQI Staging System

The National Kidney Foundation published the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, establishing the five-stage CKD classification based on glomerular filtration rate (GFR) that remains foundational today.

2012 • KDIGO CGA Classification

Kidney Disease: Improving Global Outcomes (KDIGO) refined CKD staging by incorporating cause, GFR category, and albuminuria category (CGA classification), improving prognostic stratification and guiding individualized management.

Despite these advances in classification and renal replacement therapy, CKD remains a condition frequently diagnosed late, often after irreversible nephron loss has already occurred. The central clinical question that drives this lesson is: How do we identify, stage, slow, and manage the systemic complications of progressive nephron loss before patients reach dialysis dependence? Answering this question requires a thorough understanding of CKD pathophysiology, staging, and the cascade of metabolic and cardiovascular derangements that accompany declining GFR.

SECTION 2

Core Principles & Definitions

Chronic kidney disease is formally defined as abnormalities of kidney structure or function persisting for greater than three months, with implications for health. The diagnosis requires either a GFR less than 60 mL/min/1.73 m² or the presence of markers of kidney damage such as albuminuria (albumin-to-creatinine ratio ≥ 30 mg/g), urinary sediment abnormalities, electrolyte disturbances due to tubular disorders, histological abnormalities, structural abnormalities detected by imaging, or a history of kidney transplantation. Importantly, the three-month duration criterion distinguishes CKD from acute kidney injury (AKI), although the two entities can coexist and each predisposes to the other.

GFR as the Gold Standard

The glomerular filtration rate reflects the total volume of plasma filtered by the glomeruli per unit time. It is estimated (eGFR) using serum creatinine or cystatin C–based equations such as the CKD-EPI formula. The eGFR is the primary metric used to stage CKD.

Albuminuria as a Damage Marker

Persistent albuminuria (UACR ≥ 30 mg/g) indicates glomerular barrier dysfunction and is an independent predictor of CKD progression and cardiovascular events. KDIGO classifies albuminuria into three categories: A1 (< 30 mg/g), A2 (30–300 mg/g), and A3 (> 300 mg/g).

Nephron Loss & Hyperfiltration

As nephrons are destroyed, remaining nephrons undergo compensatory hyperfiltration mediated by increased single-nephron GFR. This adaptive response maintains total GFR initially but promotes glomerulosclerosis and accelerates further nephron loss—a self-perpetuating cycle.

RAAS Activation

The renin-angiotensin-aldosterone system (RAAS) is chronically activated in CKD, raising intraglomerular pressure, promoting proteinuria, stimulating fibrosis, and contributing to systemic hypertension. RAAS blockade with ACE inhibitors or ARBs is the cornerstone of nephroprotective therapy.

CKD Staging (G1–G5)

CKD is staged by eGFR: G1 (≥ 90, with damage markers), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), and G5 (< 15 mL/min/1.73 m²). Stage G5 with symptoms or need for renal replacement is designated end-stage renal disease (ESRD).

✦

KEY TAKEAWAY

Think of the kidney as a factory with millions of identical assembly lines (nephrons). When lines are permanently shut down, the remaining lines ramp up production (hyperfiltration) to meet demand. While output stays stable at first, the overworked lines eventually burn out faster, creating a vicious cycle that accelerates the factory's decline. Blocking RAAS is like installing speed limiters on the surviving assembly lines—each one works at a sustainable pace, preserving the factory longer.

SECTION 3

Visual Explanation — CKD Staging & Progression

The diagram illustrates the KDIGO CKD staging system. The top gradient bar maps eGFR values to stages G1 through G5, with green representing preserved function and pink representing end-stage disease. Below, clinical feature cards summarize management priorities at each stage. The bottom row depicts the three albuminuria categories (A1, A2, A3), which combine with GFR stage to produce a heat-map risk matrix guiding referral and treatment intensity.

The visual above captures the dual-axis nature of CKD classification. A patient with an eGFR of 50 mL/min/1.73 m² (stage G3a) and albuminuria of 350 mg/g (category A3) carries a substantially higher risk of progression to ESRD than a patient at the same GFR stage with albuminuria below 30 mg/g. This is why KDIGO emphasizes assessing both eGFR and albuminuria at every clinical encounter. The trajectory of eGFR decline—typically 1–2 mL/min/year in uncomplicated CKD but potentially exceeding 5 mL/min/year in uncontrolled diabetic nephropathy—further refines prognostic assessment and should be tracked longitudinally using at least three measurements over a minimum of 90 days.

SECTION 4

Pathophysiological Mechanisms of CKD Progression

Understanding the mechanistic pathways that drive CKD progression is essential for both USMLE questions and clinical practice. The two predominant etiologies of CKD in developed nations—diabetes mellitus (approximately 40% of cases) and hypertension (approximately 25%)—converge on shared final common pathways involving glomerular hyperfiltration, proteinuria-induced tubular injury, interstitial fibrosis, and vascular rarefaction.

Estimating GFR: The CKD-EPI Equation

CKD-EPI CREATININE EQUATION (2021 RACE-FREE)

eGFR = 142 × min(SCr / κ, 1)ᵅ × max(SCr / κ, 1)⁻¹·²⁰⁰ × 0.9938ᴬᵍᵉ × (1.012 if female)

SCr = serum creatinine (mg/dL); κ = 0.7 (female) or 0.9 (male); α = −0.241 (female) or −0.302 (male); min = minimum of SCr/κ or 1; max = maximum of SCr/κ or 1. The 2021 CKD-EPI equation removes the race coefficient to reduce health disparities.

Hyperfiltration and the Proteinuria–Fibrosis Cycle

When nephron mass is reduced by any insult, surviving glomeruli increase their single-nephron GFR through afferent arteriolar dilation and efferent arteriolar constriction mediated by angiotensin II. The resulting elevated intraglomerular capillary pressure damages the glomerular basement membrane, allowing albumin and other proteins to leak into the tubular lumen. Filtered proteins are directly toxic to proximal tubular epithelial cells, activating proinflammatory and profibrotic pathways including NF-κB, TGF-β, and complement. The downstream effect is tubulointerstitial fibrosis and peritubular capillary loss, which further reduces the functioning nephron mass and perpetuates the cycle.

COCKCROFT-GAULT (HISTORICAL REFERENCE)

CrCl = [(140 − Age) × Weight (kg)] / [72 × SCr (mg/dL)] × (0.85 if female)

CrCl = creatinine clearance in mL/min. While largely replaced by CKD-EPI for staging, the Cockcroft-Gault equation remains important for drug dosing adjustments in many pharmacokinetic studies.

⚠

High-Yield Point

On USMLE Step 2, remember that serum creatinine is an insensitive early marker of CKD because it does not rise above the normal range until approximately 50% of nephron function is lost. A "normal" creatinine does not exclude significant kidney disease—always consider eGFR and albuminuria.

SECTION 5

Systemic Complications of CKD

As GFR declines, the kidneys progressively lose their ability to regulate electrolyte balance, acid-base homeostasis, erythropoietin production, and mineral metabolism. The systemic complications of CKD are responsible for most of the morbidity and mortality in this population and represent a heavily tested domain on the USMLE. These complications generally become clinically significant at stages G3b–G5 (eGFR < 45 mL/min/1.73 m²), although cardiovascular risk begins to rise even at mildly reduced GFR levels.

This hub-and-spoke diagram places declining GFR at the center and radiates outward to the six major complication domains of CKD. Each box lists the principal pathophysiological features. Note that cardiovascular disease is the leading cause of death in CKD patients across all stages, not progression to ESRD.

Complication	Mechanism	Key Lab Findings	Management
Anemia of CKD	Decreased erythropoietin (EPO) production by peritubular fibroblasts; iron deficiency; uremic inhibitors of erythropoiesis	Hgb < 10 g/dL, normocytic normochromic; low reticulocyte count; ferritin and TSAT to assess iron stores	IV iron first if iron-deficient (ferritin < 500, TSAT < 30%); erythropoiesis-stimulating agents (ESAs) if Hgb < 10 g/dL; target Hgb 10–11.5 g/dL (avoid > 13)
CKD-MBD	Phosphate retention → decreased 1,25-(OH)₂ vitamin D → hypocalcemia → secondary hyperparathyroidism; FGF-23 elevation	↑ PTH, ↑ phosphorus, ↓ calcium, ↓ 1,25-(OH)₂D, ↑ FGF-23, ↑ alkaline phosphatase	Dietary phosphate restriction; phosphate binders (sevelamer, calcium acetate); calcitriol or active vitamin D analogs; calcimimetics (cinacalcet) for refractory hyperPTH
Metabolic acidosis	Impaired ammoniagenesis reduces net acid excretion; loss of bicarbonate regeneration capacity	Serum HCO₃⁻ < 22 mEq/L; initially non-anion gap, progresses to anion gap acidosis as uremic acids accumulate	Oral sodium bicarbonate supplementation to maintain HCO₃⁻ ≥ 22 mEq/L; slows CKD progression and reduces protein catabolism
Hyperkalemia	Reduced renal K⁺ excretion; exacerbated by RAAS inhibitors, metabolic acidosis, and type IV RTA	Serum K⁺ > 5.5 mEq/L; ECG: peaked T waves → widened QRS → sine wave	Low-K⁺ diet; loop diuretics; patiromer or sodium zirconium cyclosilicate for chronic management; calcium gluconate, insulin + glucose, and kayexalate for acute episodes
Cardiovascular disease	Volume overload, HTN, LVH, vascular calcification (Ca × PO₄ product), chronic inflammation, dyslipidemia	Elevated BNP, echocardiographic LVH, coronary artery calcification on CT	BP < 130/80 mmHg; RAAS blockade; SGLT2 inhibitors; statins (per KDIGO for age ≥ 50 or transplant recipients); volume management
Uremia	Accumulation of nitrogenous waste products (urea, indoxyl sulfate, p-cresyl sulfate) causing systemic toxicity	BUN > 70–100 mg/dL (variable); clinical: asterixis, pericardial friction rub, platelet dysfunction, nausea	Initiation of dialysis; uremic pericarditis is an absolute indication for emergent dialysis regardless of GFR

Major complications of CKD with mechanisms, laboratory findings, and management strategies

SECTION 6

Worked Example — CKD Case Vignette

The following USMLE-style case integrates staging, complication identification, and management in a patient with CKD.

Case: 62-Year-Old Woman with Type 2 Diabetes and Fatigue

1
Step 1 — Gather Clinical Data

A 62-year-old woman with a 15-year history of type 2 diabetes mellitus and hypertension presents with progressive fatigue over 3 months. Her medications include metformin, lisinopril, and amlodipine. Labs: serum creatinine 2.1 mg/dL (baseline 1.0 mg/dL one year ago), BUN 48 mg/dL, serum K⁺ 5.8 mEq/L, HCO₃⁻ 18 mEq/L, phosphorus 5.9 mg/dL, calcium 8.2 mg/dL, intact PTH 280 pg/mL (normal 10–65), Hgb 9.2 g/dL (normocytic), UACR 580 mg/g.
2
Step 2 — Calculate eGFR and Stage CKD

Using the CKD-EPI 2021 equation with SCr 2.1 mg/dL, age 62, female sex, the eGFR calculates to approximately 25 mL/min/1.73 m². This places her in CKD stage G4. Her UACR of 580 mg/g classifies albuminuria as category A3 (severely increased). The combined classification is G4A3, placing her in the highest risk category for progression to ESRD and cardiovascular events.

CKD Stage G4, Albuminuria A3 — Very High Risk
3
Step 3 — Identify All Complications

This patient demonstrates multiple CKD complications simultaneously. Her Hgb of 9.2 g/dL with normocytic morphology indicates anemia of CKD (likely from decreased EPO). The elevated phosphorus (5.9 mg/dL), low calcium (8.2 mg/dL), and markedly elevated PTH (280 pg/mL) constitute secondary hyperparathyroidism as part of CKD-mineral and bone disorder (CKD-MBD). The serum K⁺ of 5.8 mEq/L represents hyperkalemia, likely exacerbated by the lisinopril and the metabolic acidosis (HCO₃⁻ 18 mEq/L).

Complications: Anemia of CKD, CKD-MBD with secondary hyperPTH, hyperkalemia, metabolic acidosis
4
Step 4 — Management Plan

Management must address each complication while preserving nephroprotection. First, obtain an ECG to evaluate for hyperkalemia-related changes; if peaked T waves or QRS widening is present, administer IV calcium gluconate for membrane stabilization, then insulin + glucose and consider kayexalate. Do not discontinue the ACE inhibitor unless K⁺ remains uncontrollable—the renoprotective benefit generally outweighs the hyperkalemia risk if it can be managed with dietary restriction, sodium bicarbonate, and potassium binders (patiromer). Start oral sodium bicarbonate to target HCO₃⁻ ≥ 22 mEq/L. For anemia, check iron studies: if ferritin < 500 ng/mL and TSAT < 30%, give IV iron before starting an ESA. For CKD-MBD, restrict dietary phosphate, start a phosphate binder (sevelamer), and consider calcitriol once phosphorus is controlled. Discontinue metformin (eGFR < 30 mL/min/1.73 m², risk of lactic acidosis) and switch to insulin. Refer to nephrology for AV fistula planning, as ESRD may occur within 1–3 years at this trajectory.

Immediate: ECG → treat hyperkalemia. Chronic: maintain ACE inhibitor, NaHCO₃, phosphate binder, IV iron ± ESA, discontinue metformin, nephrology referral for dialysis access planning.

SECTION 7

Pharmacotherapy — Strengths & Limitations

The therapeutic armamentarium for CKD has expanded substantially in recent years, with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) joining RAAS inhibitors as pillars of nephroprotective therapy. Understanding the strengths and limitations of each drug class is essential for both Step 2 and clinical practice.

Drug Class	Strengths	Limitations / Risks
ACE Inhibitors / ARBs	Reduce intraglomerular pressure, decrease proteinuria by 30–40%, slow GFR decline, CV benefit; first-line for all CKD patients with albuminuria	Hyperkalemia, acute GFR drop (up to 30% acceptable), teratogenic; dual RAAS blockade (ACEi + ARB) increases adverse events without benefit (ONTARGET trial)
SGLT2 Inhibitors (e.g., dapagliflozin, empagliflozin)	Reduce intraglomerular pressure via tubuloglomerular feedback; slow CKD progression independent of diabetes status (DAPA-CKD, EMPA-KIDNEY); reduce HF hospitalizations	Genital mycotic infections; DKA risk (less relevant in non-diabetics); initial eGFR dip (hemodynamic, reversible); limited data for eGFR < 20; generally started if eGFR ≥ 20
nsMRAs (finerenone)	Reduces proteinuria and CKD progression; anti-inflammatory and anti-fibrotic effects; lower hyperkalemia risk than steroidal MRAs (spironolactone)	Still carries hyperkalemia risk (monitor K⁺); approved for CKD with T2DM; limited evidence in non-diabetic CKD
Erythropoiesis-Stimulating Agents (ESAs)	Effective correction of anemia; reduce transfusion dependence; improve quality of life and exercise tolerance	Targeting Hgb > 13 g/dL increases thromboembolic events and mortality (TREAT, CREATE trials); hypertension; pure red cell aplasia (rare, anti-EPO antibodies)
Phosphate Binders	Reduce serum phosphorus; sevelamer also lowers LDL and may reduce vascular calcification; essential for CKD-MBD management	Calcium-based binders may promote vascular calcification (use with caution if Ca × PO₄ elevated); GI side effects; high pill burden reduces adherence

Comparison of major pharmacologic agents in CKD management

✦

KEY TAKEAWAY

Modern CKD management follows a layered approach—analogous to building a dam with multiple barriers. ACE inhibitors/ARBs form the foundation, SGLT2 inhibitors add a second independent barrier, and finerenone provides a third layer for diabetic CKD. Together, these three classes address hemodynamic, inflammatory, and fibrotic drivers of progression—a paradigm shift from the era of RAAS blockade alone.

SECTION 8

CKD vs. AKI vs. AKI-on-CKD — Advanced Distinctions

A common clinical and examination challenge is distinguishing between acute kidney injury, chronic kidney disease, and acute kidney injury superimposed on chronic kidney disease (AKI-on-CKD). The distinction carries profound management and prognostic implications: AKI is potentially reversible, CKD is generally not, and AKI-on-CKD accelerates progression to ESRD. Features suggesting chronicity include bilateral small kidneys on ultrasound (< 9 cm), cortical thinning, increased echogenicity, the presence of broad waxy casts in the urine, and evidence of longstanding complications such as renal osteodystrophy or anemia. In contrast, normal-sized or enlarged kidneys, an acute rise in creatinine over days, and a bland or active urine sediment may point toward AKI.

Feature	AKI	CKD	AKI-on-CKD
Time course	Hours to days	≥ 3 months	Acute rise on chronic baseline
Kidney size (US)	Normal or enlarged	Small (< 9 cm), echogenic	Small with acute changes
Prior baseline SCr	Normal	Elevated, stable	Elevated, then acute rise
Anemia / CKD-MBD	Typically absent	Present	Present at baseline
Reversibility	Often reversible	Irreversible	Acute component may reverse
Broad waxy casts	Absent	Present	Present with active sediment

Distinguishing AKI, CKD, and AKI-on-CKD

Looking forward, novel biomarkers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and soluble urokinase plasminogen activator receptor (suPAR) are being investigated to improve early detection of both AKI and CKD progression. Additionally, clinical trials of endothelin receptor antagonists, Nrf2 activators (bardoxolone), and anti-complement therapies may further expand the therapeutic landscape in coming years. Understanding the foundational concepts covered in this lesson will be essential for integrating these emerging treatments into clinical practice.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A medical student asks why CKD patients develop secondary hyperparathyroidism. Explain the pathophysiological sequence beginning with phosphate retention and ending with elevated PTH levels. Include the role of vitamin D in this cascade.

Show answer

As GFR declines, the kidneys lose the ability to excrete phosphate, leading to hyperphosphatemia. Elevated serum phosphorus directly suppresses the renal enzyme 1α-hydroxylase, which converts 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D (calcitriol). Decreased calcitriol reduces intestinal calcium absorption, resulting in hypocalcemia. The combination of hypocalcemia, hyperphosphatemia, and low calcitriol levels stimulates the parathyroid glands to increase PTH secretion. Additionally, elevated FGF-23 (an early adaptive response to phosphate load) independently suppresses 1α-hydroxylase and directly inhibits PTH but eventually becomes overwhelmed as the parathyroid glands undergo hyperplasia. Over time, this leads to the markedly elevated PTH levels characteristic of secondary hyperparathyroidism in CKD.

Question 2: BASIC CALCULATION

A 70-year-old male weighing 80 kg has a serum creatinine of 2.0 mg/dL. Using the Cockcroft-Gault equation, estimate his creatinine clearance. Based on this value, what CKD stage would be most appropriate?

Show answer

Using the Cockcroft-Gault equation: CrCl = [(140 − 70) × 80] / [72 × 2.0] = [70 × 80] / 144 = 5600 / 144 ≈ 38.9 mL/min. Since this patient is male, no additional correction is needed. A creatinine clearance of approximately 39 mL/min corresponds to CKD stage G3b (eGFR 30–44 mL/min/1.73 m²). Note that the Cockcroft-Gault equation estimates creatinine clearance (not exactly GFR), and it is not adjusted for body surface area, but it provides a reasonable clinical estimate. At this stage, the patient should be monitored for CKD-MBD, anemia, metabolic acidosis, and hyperkalemia, with nephrology referral considered.

Question 3: INTERMEDIATE

A 55-year-old woman with CKD stage G4 on lisinopril and dapagliflozin presents with a serum potassium of 6.1 mEq/L. Her ECG shows peaked T waves but no QRS widening. Outline the immediate and chronic management steps. Should either nephroprotective medication be discontinued?

Show answer

Immediate management of hyperkalemia with ECG changes includes: (1) IV calcium gluconate for cardiac membrane stabilization (does not lower K⁺ but protects the heart); (2) IV insulin (10 units regular) with 25 g dextrose to shift K⁺ intracellularly; (3) nebulized albuterol as an adjunctive K⁺-lowering agent; (4) assessment for other reversible causes such as metabolic acidosis (treat with sodium bicarbonate if HCO₃⁻ < 22). For chronic management, dietary potassium restriction should be reinforced, and a potassium binder such as patiromer or sodium zirconium cyclosilicate should be initiated. The decision to discontinue nephroprotective agents requires clinical judgment: if K⁺ can be controlled with binders and dietary modification, both lisinopril and dapagliflozin should be continued given their substantial renoprotective and cardiovascular benefits. However, if hyperkalemia recurs despite maximal potassium-lowering strategies, lisinopril is more likely to be the primary contributor and should be dose-reduced or switched to a calcium channel blocker. SGLT2 inhibitors have a smaller effect on K⁺ and should generally be continued.

Question 4: APPLIED

A 60-year-old man with CKD stage G3b (eGFR 35) due to IgA nephropathy has a hemoglobin of 9.0 g/dL, ferritin of 150 ng/mL, and TSAT of 18%. He has no GI bleeding and his reticulocyte count is low. His physician starts epoetin alfa. Three months later, his Hgb has not improved. What is the most likely reason, and what should be done next?

Show answer

The most likely reason for ESA resistance in this patient is functional iron deficiency. Although his ferritin of 150 ng/mL is not critically low, his transferrin saturation (TSAT) of 18% is below the target threshold of 30% recommended for CKD patients on ESAs. In the setting of chronic inflammation inherent to CKD, ferritin may be falsely elevated as an acute-phase reactant, masking true iron deficiency. The next step is to administer intravenous iron (e.g., ferric carboxymaltose or iron sucrose) to replenish iron stores, targeting a ferritin of 200–500 ng/mL and TSAT of 30–50%. Other causes of ESA hyporesponsiveness to consider include undiagnosed GI bleeding, chronic infection or inflammation, hyperparathyroidism (which suppresses erythropoiesis), aluminum toxicity, B12/folate deficiency, and rarely, pure red cell aplasia from anti-EPO antibodies—though this last entity is extremely rare with modern recombinant EPO formulations.

Question 5: CRITICAL THINKING

A 48-year-old woman with type 2 diabetes, CKD stage G3a (eGFR 52), and a UACR of 450 mg/g is currently on losartan 100 mg daily and metformin 1000 mg twice daily. Her HbA1c is 7.8%, BP is 142/88, and K⁺ is 4.8 mEq/L. Design a comprehensive medication optimization plan using current KDIGO guidelines, justifying the addition of each agent. Discuss the expected physiological effects and monitoring parameters for the first 3 months.

Show answer

This patient with diabetic CKD at high risk for progression warrants a multi-targeted approach. First, her BP is above the 130/80 target; since she is already on maximum-dose losartan, add a dihydropyridine CCB (e.g., amlodipine) or a thiazide-like diuretic (chlorthalidone) rather than a second RAAS blocker. Second, an SGLT2 inhibitor (dapagliflozin or empagliflozin) should be initiated regardless of glycemic control, as trials (DAPA-CKD, CREDENCE) demonstrate nephroprotective benefit independent of HbA1c reduction. Expect an initial eGFR dip of 3–5 mL/min in the first 2 weeks—this is hemodynamic (reduced intraglomerular pressure via tubuloglomerular feedback) and is associated with better long-term outcomes. Third, consider finerenone based on the FIDELIO-DKD and FIGARO-DKD trials, which showed reduced CKD progression and CV events in patients with diabetic CKD already on RAAS blockade. Monitor K⁺ closely (baseline K⁺ 4.8 is acceptable but leaves limited buffer). Fourth, her metformin dose should be reduced to 1000 mg daily at eGFR < 45 and discontinued at eGFR < 30. Monitoring over 3 months should include: serum creatinine and eGFR at 2 weeks (to assess expected hemodynamic dip from SGLT2i), then monthly; K⁺ at 1 week, 4 weeks, and 3 months after each RAAS-modifying agent change; UACR at 3 months to assess response (target > 30% reduction); BP at every visit; HbA1c at 3 months; and a urinalysis to monitor for genital mycotic infections as an SGLT2i side effect. This layered approach addresses hemodynamic, inflammatory, metabolic, and fibrotic drivers of CKD progression simultaneously.

SUMMARY

Chronic Kidney Disease — Key Concepts Review

Summary

Chronic kidney disease is defined as kidney damage or eGFR < 60 mL/min/1.73 m² persisting for ≥ 3 months. It is staged using the KDIGO system combining GFR category (G1–G5) and albuminuria category (A1–A3). The two most common etiologies are diabetes mellitus and hypertension. Progressive nephron loss triggers compensatory hyperfiltration and RAAS activation, which initially maintain GFR but ultimately accelerate glomerulosclerosis and fibrosis.

Major complications include anemia (decreased EPO), CKD-MBD with secondary hyperparathyroidism, metabolic acidosis, hyperkalemia, and cardiovascular disease—the leading cause of death in CKD. The cornerstone of nephroprotection is RAAS blockade (ACEi/ARB), now complemented by SGLT2 inhibitors and finerenone in diabetic CKD. Management also requires treatment of each complication: IV iron ± ESAs for anemia, phosphate binders and vitamin D analogs for CKD-MBD, sodium bicarbonate for acidosis, and dietary modification with potassium binders for hyperkalemia. Uremic pericarditis is an absolute indication for emergent dialysis. At stage G4, nephrology referral and dialysis access planning are essential.